FDA decision: Iberdomide by Celgene (in 2026)

FDA decision on Iberdomide in 2026 If the FDA's decision on Iberdomide by Celgene in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Iberdomide is an experimental oral pill developed by Bristol Myers Squibb (under the Celgene banner) to treat multiple myeloma, a cancer of the blood's plasma cells. T